Results 181 to 190 of about 413,940 (274)

Targeted mitochondrial therapy for pancreatic cancer. [PDF]

Transl Oncol
Zhao X, Wu G, Tao X, Dong D, Liu J.
europepmc   +1 more source

Fatty acids for treating pancreatic cancer [PDF]

, 1994
Stephen J. Wigmore, J. Falconer, Kenneth C.H. Fearon   +2 more
openalex   +1 more source

Antigen‐Targeting Inserted Nanomicelles Guide Pre‐Existing Immunity to Kill Head and Neck Cancer

Advanced Science, EarlyView.
This study introduces a tumor‐targeted nanomicelle platform (preS1‐pHLIP) that exploits pre‐existing antiviral immunity to combat heterogeneous cancers. By delivering viral antigens to label tumors as virus‐like targets, the nanomicelles activate antiviral B and T cells, triggering in situ tumor lysis.
Lizhuo Zhang, Qingqing Feng, Chuanming Zheng, Yuanqiang Li, Xinyang Ge, Tiefeng Jin, Gaofeng Hu, Zhuo Tan, Jiafeng Wang, Jiajie Xu, Liehao Jiang, Dan Wang, Zhangguo Ying, Xiao Zhao, Keman Cheng, Qinglin Li, Minghua Ge   +16 more
wiley   +1 more source

The Evolutionary Forest of Pancreatic Cancer. [PDF]

Cancer Discov
Mullen KM, Hong J, Attiyeh MA, Hayashi A, Sakamoto H, Kohutek ZA, McIntyre CA, Zhang H, Makohon-Moore AP, Zucker A, Wood LD, Myers MA, Arnold BJ, Zaccaria S, Chou JF, Capanu M, Socci ND, Raphael BJ, Iacobuzio-Donahue CA.   +18 more
europepmc   +1 more source

DNA analysis of pancreatic cancer. With special reference to the tumor size and the histological findings.

, 1988
Hajime Katagiri
openalex   +2 more sources

A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/ WGA) assessed in combination with CA 19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer [PDF]

, 1992
N. Parker, C. A. Makin, CK Ching, D. Eccleston, Oliver Taylor, Daniel T. Milton, Jonathan M. Rhodes   +6 more
openalex   +1 more source

Targeting Replication Fork Processing Synergizes with PARP Inhibition to Potentiate Lethality in Homologous Recombination Proficient Ovarian Cancers

Advanced Science, EarlyView.
This study demonstrates that the resveratrol analogue, trans‐4,4′‐dihydroxystilbene (DHS), exhibits synergistic anti‐tumor activity with the PARP inhibitor talazoparib, inducing significant ovarian cancer cell death. The synergistic effect of this combination arises from the concurrent downregulation of homologous recombination factors and the ...
Ganesh Pai Bellare, Kshama Kundu, Papiya Dey, Krupa Thankam Philip, Nitish Chauhan, Muskan Sharma, Sankarsingh Kesharsingh Rajput, Birija Sankar Patro   +7 more
wiley   +1 more source

Lipidome atlas of p53 mutant variants in pancreatic cancer. [PDF]

Biol Direct
Cotton K, Comer C, Caporali S, Butera A, Gurres S, Capradossi F, D'Alessandro A, Amelio I, Niklison-Chirou MV.   +8 more
europepmc   +1 more source

HNF3α Targets Nckap1l and Promotes Renal Fibrosis Following Ischemia‐Reperfusion Injury

Advanced Science, EarlyView.
Hepatocyte Nuclear Factor 3 alpha (HNF3α) is significantly upregulated in renal tubular epithelial cells of CKD patients and fibrotic mice. Deletion of HNF3α mitigates IRI‐induced renal fibrosis, while overexpression worsens it. HNF3α directly regulates NCK‐associated protein 1‐like (Nckap1l), whose overexpression exacerbates fibrosis.
Ling Hou, Yan Guo, Shuang Xu, Mi Bai, Weidong Cao, Yue Zhang, Zhanjun Jia, Aihua Zhang   +7 more
wiley   +1 more source

PRMT5 inhibitors: Therapeutic potential in pancreatic cancer. [PDF]

Transl Oncol
Schneider C, Spielmann V, Braun CJ, Schneider G.   +3 more
europepmc   +1 more source